IMMUNOSUPPRESSION INDUCED BY THE FRIEND MURINE LEUKEMIA VIRUS COMPLEX IN MICE WITH THE RFV-3R/S GENOTYPE NLM AIDSLINE Important note: Information in this article was accurate in 1987. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


IMMUNOSUPPRESSION INDUCED BY THE FRIEND MURINE LEUKEMIA VIRUS COMPLEX IN MICE WITH THE RFV-3R/S GENOTYPE

Animal Models of Retrovirus Infection and Their Relationship to AIDS. Salzman LA, ed. Orlando, Florida, Academic Press, p. 279-84, 1986.. Unique Identifier : AIDSLINE ICDB/87629282
Morrison RP; Nishio J; Chesebro B; Lab. of Persistent Viral Diseases, Rocky Mountain Lab., Natl.; Inst. of Allergy and Infectious Diseases, NIH, Hamilton, MT


Abstract: Infection by oncogenic retroviruses is frequently associated with immunosuppression. In the case of the erythroleukemia-inducing Friend murine leukemia virus complex (FV), suppression of functions of B lymphocytes, T lymphocytes, and macrophages has been observed in infected and leukemic mice; however, some mouse strains develop a strong anti-FV humoral immune response during the course of active FV infection. Anti-FV antibody made in mice with the Rfv-3(r/s) genotype, such as (B10.A x A)F1 mice, was found to eliminate established viremia and to reduce levels of virus-releasing cells in the spleen by 10,000-fold, in spite of the continued presence of leukemic splenomegaly. Because of the unusual coexistence of a significant antiviral immune response and progressive leukemia, the (B10.A x A)F1 mice were tested for their ability to respond immunologically to nonviral antigens during the course of FV leukemia. Groups of the mice were inoculated with sheep red blood cells (SRBC) 18 or 21 days after FV infection, and their spleens were analyzed for plaque-forming cells (PFC) 7 or 4 days later, respectively. The results indicated that splenic anti-SRBC PFC responses were suppressed during infection in both Rfv-3(r/s) and Rfv-3(s/s) mouse strains. The suppression of IgG PFC at day 7 was more extensive than the suppression of IgM PFC at day 4 or at day 7. The IgM PFC response in infected (B10.A x A)F1 mice was actually higher on day 7 than on day 4; in contrast; the IgM PFC in uninfected control mice always decreased significantly between days 4 and 7. This suggested that in FV-infected (B10.A x A)F1 mice the IgM anti-SRBC response might have been delayed kinetically, rather than simply suppressed in magnitude. It was not possible to conclude which cells in the immune system were affected by the FV infection. The mechanism of immunosuppression by FV is unclear. There are several interesting similarities between the status of FV-infected (B10.A x A)F1 mice and AIDS virus-infected human patients. In both cases individuals are immunosuppressed and both have detectable antiviral antibodies. Furthermore, expression of infectious virus is limited, making virus isolation difficult to achieve. (8 Refs)
Keywords: Animal Antibodies, Viral/ANALYSIS Friend Virus/GENETICS/*IMMUNOLOGY Genes, Viral Genotype *Immune Tolerance Leukemia, Erythroblastic, Acute/*IMMUNOLOGY Leukemia, Experimental/*IMMUNOLOGY Mice Mice, Inbred BALB C Plaque Assay MONOGRAPH

KWDanimalantibodies,viral/analysisfriendvirus/genetics/KWDimmunologygenes,viralgenotypeKWDimmunetoleranceleukemia,erythroblastic,acute/KWDimmunologyleukemia,experimental/KWDimmunologymicemice,inbredbalbcplaqueassaymonograph
870530
M8750349


Copyright © 1987 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1987. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1987. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .